Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action.
AMA J Ethics. 2019;21(4):E347-355. doi:
10.1001/amajethics.2019.347.
Despite challenges of decision making for unrepresented patients, few laws or policy statements offer solutions. This article offers 5 key things to do.
AMA J Ethics. 2019;21(7):E582-586. doi:
10.1001/amajethics.2019.582.
Carmel Shachar, JD, MPH and Dorit Rubinstein Reiss, LLB, PhD
Legal approaches to preserving social stability, maintaining trust, supporting therapeutic research opportunities, or diminishing disease severity deserve ethical scrutiny.
AMA J Ethics. 2020;22(1):E36-42. doi:
10.1001/amajethics.2020.36.
Jennifer Aldrich, MD, Jessica Kant, MSW, LICSW, MPH, and Eric Gramszlo
Estelle v Gamble (1976) reiterates that the 8th Amendment to the US Constitution requires adequate care to be offered to all people who are incarcerated.
AMA J Ethics. 2023;25(6):E407-413. doi:
10.1001/amajethics.2023.407.
Requirements for informed consent are relatively vague and the exceptions are few, so it is in the physician’s best interest to inform patients about proposed treatment options, ascertain that they understand their choices, and secure their consent.